CompanyInvestor RelationsStem Cell StorageCell ExpansionCell TherapiesResearch and DevelopmentCompany NewsScientific NewsContact
    
 
  • News Archive
    		•

    Professor McGuckin joins Cryo-Save as Scientific Director (12/01/2009)

    In his new role Professor McGuckin will be responsible for integrating new scientific technologies and keeping Cryo-Save’s storage services at the leading edge.


    Professor McGuckin is a stem cell pioneer who developed the first “mini-liver” from human umbilical cord blood. His team has gone on to develop cord blood cells into many other human tissues, including nervous tissue and blood vessels amongst others. Recently his team has created artificial “pancreatic islets” - producers of insulin impaired in diabetic patients, which may have major implications for the development of stem cells for the treatment of diabetes.


    In a recent interview, Professor McGuckin stated: “My vocation is to treat patients with umbilical cord blood. I believe that Cryo-Save, with their innovative and responsible program for storing cord blood will help us achieve this goal faster and for more patients on an international scale. The speed that stem cell treatments are being developed now requires that we plan for the future healthcare needs of our nations.”


    Rob Koremans, CEO of Cryo-Save, said: “Gaining such a tremendous scientific know how will help sustain our financial security and contributions to patients. Prof. McGuckin’s recruitment is an auxiliary step in our efforts to put Cryo-Save at the forefront of the global stem cell market place”.


    Working in stem cells for over 20 years, Professor McGuckin is an opinion leader who has been called upon by governments and hospitals around the world, including the US Senate, the United Nations (Geneva) and the Parliaments of France, UK, Austria and Germany. Colin McGuckin is also President of the Novus Sanguis Consortium, which was launched in 2008 under the patronage of the President of the European Parliament. Novus Sanguis brings together leading adult stem cell researchers and clinicians from across the world to work on specific diseases of the human condition, including heart disease, stroke, diabetes and organ regeneration.


     

    About Cryo-Save

    Cryo-Save is Europe’s Leading Stem Cell Bank. Headquartered in the Netherlands, the company conducts fundamental research in the field of cryopreservation techniques for stem cells. The research is done in partnership with five European universities and the Fraunhofer Institute for Biomedical Engineering (IBMT) and is part of an EU funded project CRYSTAL. The stem cell banking services of Cryo-Save are available in 38 countries across three continents (Europe, Asia, and Africa). The company offers a private-shared banking service in Italy and will start to introduce this in other countries after regulatory clearance.

     

     

     

     

    News Cryo-Save Group

    Date Title Summary 
    04/06/2010Scientists give go-ahead for private storageFour world-renowned stem cell experts have recently given their full support to private cordblood banking. The four scientists supported the "Family Cord Blood Bank" which has just been established in the US by CORD:USE.
    04/06/2010Scientists give go-ahead for private storage (Dutch version)Vier wereldvermaarde stamcelexperts* en initiatiefnemers van publieke celopslagbanken in de Verenigde Staten en Europa, hebben zich recent duidelijk uitgesproken voor de opslag van stamcellen uit navelstrengbloed in private banken. De oprichting van de ‘family Cord Blood Bank’ door CORD:USE in de VS, mocht zich verheugen in de enthousiaste medewerking van deze wetenschappeliijke experts.
    02/06/2010Cancellation noticeCryo-Save Group N.V. (AIM/Euronext: CRYO, 'Cryo-Save'; or 'the Group'), announces that further to the statement made by the Group on 22 March 2010 regarding the intention to delist its ordinary shares from trading on AIM, the Group today announces that its admission to trading on AIM will be cancelled with effect from 30 June 2010.
    28/05/2010Spain and France UpdateCryo-Save Group N.V. (AIM/Euronext: 'Cryo-Save' or 'the Group'), Europe's leading stem cell bank, announces the signing of the contract with Aresa Seguros de Salud, the health insurance company of the Spanish Mutua Madrilena Insurance Group.
    21/05/2010Cryo-Lip LaunchCryo-Save Group N.V. (Euronext/AIM: CRYO, 'Cryo-Save' or 'the Group'), Europe's leading stem cell bank, announces the European launch of Cryo-Lip®, a new product that allows the collection, processing and storage of a rich mixture of adult stem cells from liposuction aspirate (fatty tissue that is normally discarded). A new cryopreservation process for fatty tissue has been developed and submitted for international patent by Cryo-Save.
    21/05/2010Cryo-Lip Launch (Dutch version)Cryo-Save Group N.V. (Euronext/AIM: CRYO, “Cryo-Save” of “de Groep”), Europa’s grootste stamcelbank, maakt de Europese introductie bekend van Cryo-Lip®, een nieuw product waarmee een rijk mengsel van volwassen stamcellen uit liposuctievet (vetweefsel dat normaal gesproken wordt weggegooid) kan worden verzameld, verwerkt en opgeslagen. Cryo-Save heeft een nieuw cryopreservatieproces (bewaring bij zeer lage temperaturen) voor vetweefsel ontwikkeld en hiervoor een internationale octrooiaanvraag ingediend.
    19/05/2010AGM Result 19 May 2010Cryo-Save Group N.V. (Euronext/AIM: CRYO, 'Cryo-Save' or 'the Group'), Europe's leading stem cell bank, announces that all resolutions at today's AGM were passed.
    19/05/2010AGM Result 19 May 2010 (Dutch version)Cryo-Save Group N.V. (Euronext/AIM: CRYO, 'Cryo-Save' of 'de Groep'), Europa's grootste stamcelbank, maakt bekend dat alle voorstellen aan de Algemene Vergadering van Aandeelhouders, welke hedenmiddag plaatsvond te Zutphen, zijn aangenomen.
    17/05/2010Director/PDMR ShareholdingCryo-Save Group N.V.(AIM/Euronext: CRYO, 'Cryo-Save', or 'the Group'), Europe's leading stem cell bank, has been informed today that Mr Johan Goossens, Chairman, purchased 25,000 ordinary shares of Euro 0.10 ('Ordinary Shares') at €5.78 on 14 May 2010.
    17/05/2010Director/PDMR Shareholding (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, 'Cryo-Save', of 'de Groep'), de grootste stamcelbank van Europa is vandaag geïnformeerd dat de heer Johan Goossens, Chairman, 25.000 aandelen Cryo-Save heeft gekocht tegen €5,78 op 14 mei 2010.
    10/05/2010Trading update Q1 2010Cryo-Save Group N.V. (AIM/Euronext: CRYO, or 'the Group'), Europe's leading stem cell bank, announces its trading update for the three months to 31 March 2010.
    10/05/2010Trading update Q1 2010 (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, of 'de Groep'), de grootste stamcelbank van Europa, publiceert vandaag haar trading update over het eerste kwartaal van 2010.
    04/05/2010Notice of Annual General Meeting 2010Cryo-Save Group N.V. (AIM/Euronext: CRYO, 'Cryo-Save', or 'the Group'), Europe's leading stem cell bank, announces that the Group's Annual General Meeting (AGM) will be held on Wednesday, 19 May 2010 at 14:00 hours CET at IJsselpaviljoen, IJsselkade 1, 7201 HA Zutphen, the Netherlands.
    04/05/2010Annual General Meeting 2010 (Dutch Version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, of ’de Groep’), de grootste stamcelbank van Europa maakt bekend dat haar Algemene Vergadering van Aandeelhouders zal worden gehouden op woensdag 19 mei 2010, aanvang om 14:00 uur in het IJsselpaviljoen, IJsselkade 1, 7201 HA te Zutphen.
    29/04/2010Grant of share optionsCryo-Save Group N.V. (AIM/Euronext: CRYO, ‘Cryo-Save’ or ‘the Group’), Europe's leading stem cell bank, announces that on 28 April 2010 the Group granted options to subscribe for ordinary shares in the Company under the Cryo-Save Group 2009 Share Option Scheme.
    29/04/2010Toekenning aandelen optiesCryo-Save Group N.V. (AIM/Euronext: CRYO, of ’de Groep’), de grootste stamcelbank van Europa maakt bekend dat door de Groep op 28 april 2010 opties zijn toegekend op haar aandelen onder het 2009 Share Option Scheme.
    19/04/2010Annual Report and Accounts 2009Cryo-Save Group N.V. (AIM/Euronext: CRYO, or "the Group"), Europe's leading stem cell bank, confirms that its annual report and accounts for the year ended 31 December 2009 is now available on the Group's website, www.cryo-savegroup.com.
    12/04/2010Director/PDMR ShareholdingCryo-Save Group N.V.(AIM/Euronext: CRYO, or ‘the Group’), Europe’s leading stem cell bank, has been informed that Mr Marc Waeterschoot, Chief Executive Officer, purchased 17,296 ordinary shares.
    12/04/2010Director/PDMR Shareholding (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, of “de Groep”), de grootste stamcelbank van Europa is geïnformeerd dat de heer Marc Waeterschoot, Chief Executive Officer, 17.296 aandelen Cryo-Save heeft gekocht in de periode van 7 april tot en met 9 april 2010.
    30/03/2010Director/PDMR ShareholdingCryo-Save Group N.V.(AIM/Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), Europe’s leading stem cell bank, has been informed today that Mr Johan Goossens, Chairman, purchased 17,873 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price range between €5.60 and €5.84 between 23 March and 26 March 2010.
    30/03/2010Director/PDMR Shareholding (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, “Cryo-Save”, of “de Groep”), de grootste stamcelbank van Europa is vandaag geïnformeerd dat de heer Johan Goossens, Chairman, 17.873 aandelen Cryo- Save heeft gekocht in de periode van 23 maart tot en met 26 maart 2010. De aankoopprijs lag tussen €5,60 en €5,84.
    26/03/2010Director/PDMR ShareholdingCryo-Save Group N.V., Europe’s leading stem cell bank, has been informed that on 25 March 2010 Marc Waeterschoot, Chief Executive Officer, transferred 100,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) from Life-Sciences N.V., a company controlled by him, into his personal Cryo-Save holdings.
    22/03/2010Cryo-Save Full Year Results (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save", of "de Groep"), de grootste stamcelbank van Europa, maakt haar resultaten bekend over het boekjaar eindigend op 31 December 2009.
    22/03/2010Cryo-Save Full Year ResultsCryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save", or "the Group"), Europe's leading adult stem cell storage bank, has published its full year results for the year to 31 December 2009.
    19/03/2010Non-Executive Director appointmentCryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save" or "the Group"), Europe's leading stem cell bank, announces that Dr. Ronald H.W. Lorijn will be appointed as Non-Executive Director...
    19/03/2010Non-Executive Director appointment (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO), Europa’s grootste stamcelbank, maakt bekend dat dr. Ronald H.W. Lorijn (58) (MD, PhD, MBA) zal worden voorgedragen voor benoeming tot Non-Executive Director...
    26/02/2010Acquisition of minority shareholdingsCryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save" or "the Group"), Europe's leading stem cell bank, has acquired the remaining 30% minority shareholding of its...
    26/02/2010Acquisition of minority shareholdings (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, “Cryo-Save” of “de Groep”), de grootste stamcelbank van Europa, heeft het resterende 30% minderheidsbelang gekocht van haar...
    24/02/2010Notice of Full Year resultsCryo-Save Group NV, (AIM: CRYO), Europe's largest adult stem cell storage bank, will be publishing its Full Year results for the 12 months ended 31 December 2009 on Monday, 22 March 2010.
    24/02/2010Notice of Full Year results (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, “Cryo-Save” of “de Groep”), de grootste stamcelbank van Europa, zal haar resultaat over het jaar eindigend op 31 december 2009 publiceren op maandag 22 maart 2010.
    04/02/2010New CEO AppointmentCryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save" or "the Group"), Europe's leading stem cell bank, has appointed Arnoud van Tulder (48) as Chief Executive Officer with effect from 1 May 2010.
    04/02/2010New CEO Appointment (Dutch Version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, “Cryo-Save” of “de Groep”), de grootste stamcelbank van Europa, kondigt aan dat Arnoud van Tulder (48), momenteel Chief Financial Officer van de Groep, met ingang van 1 mei 2010 zal worden benoemd tot Chief Executive Officer.
    27/01/2010Board ChangeCryo-Save Group N.V. (AIM/Euronext: CRYO, “Cryo-Save” or “the Group”), Europe’s leading stem cell bank, announces that Werner Spinner, a non-executive director, has resigned from the Board with immediate effect.
    27/01/2010Board Change (Dutch version)Cryo-Save Group N.V. (AIM/Euronext: CRYO, “Cryo-Save” of “de Groep”), de grootste stamcelbank van Europa, maakt bekend dat Werner Spinner met ingang van heden is teruggetreden als non-executive director uit de Board of Directors.
    12/03/2009100,000th sample under storageWe are proud to be able to announce that we now have saved the stem cells from over 100,000 children. This significant landmark was reached a few days ago when the stem cells from the one hundred thousandth newborn child were safely stored in our facilities.
    12/01/2009Professor McGuckin joins Cryo-Save as Scientific DirectorCryo-Save are pleased to announce the new appointment of Professor McGuckin as Scientific Director to the group on 5th of January 2009.
    		  
      europe flag
    Europe's leading stem cell bank -
    4 laboratories - 39 countries -
    3 continents


    Use of this website signifies your agreement to the Disclaimer.
    ©2009 Cryo-Save Group N.V. All rights reserved.